CGTX
Cognition Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$107.40M
P/E Ratio
—
EPS
$-0.23
Beta
1.75
52W High
$3.83
52W Low
$0.25
50-Day MA
$1.16
200-Day MA
$1.41
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of small molecule therapies targeting age-related degenerative diseases and disorders of the central nervous system and retina. The company is headquartered in Purchase, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-42.82M |
| Operating Margin | 0.00% |
| Return on Equity | -88.60% |
| Return on Assets | -76.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.39 |
| Price-to-Book | 3.59 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $89.50M |
| Float | $81.85M |
| % Insiders | 2.25% |
| % Institutions | 23.49% |
Historical Volatility
HV 10-Day
85.08%
HV 20-Day
86.60%
HV 30-Day
74.54%
HV 60-Day
132.46%
HV Rank
11.1%
Volatility is currently expanding
Analyst Ratings
Consensus ($3.50 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026